シェバ医療センター
| イスラエル | トルコ | オーストリア | |
| 骨髄移植術 | から $144,000 | から $36,000 | から $140,000 |
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Israeli oncology centers follow evidence-based protocols using Berlin-Frankfurt-Münster (BFM) regimens. Treatment focuses on risk-stratified chemotherapy across induction and consolidation phases. Pediatric and young adult protocols prioritize non-myelosuppressive agents. Advanced care includes CAR T-cell therapy and allogeneic stem cell transplants for high-risk cases.
Bookimed Expert Insight: Israeli centers utilize a pediatric-inspired regimen for adults up to age 45. This approach significantly improves survival rates compared to traditional adult chemotherapy. Facilities like Sheba Medical Center often lead these clinical transitions. Patients benefit from protocols that use higher doses of asparaginase. This shift mirrors success seen in pediatric BFM study groups. Choosing a center with integrated pediatric and adult hematology departments ensures smoother protocol transitions.
Patient Consensus: Patients note the comprehensive nature of supportive care, including psychosocial help. They often highlight the speed of transitioning to advanced immunotherapies when standard chemo fails.
Acute lymphoblastic leukemia chemotherapy in Israel is highly safe. Hospitals follow American and European oncology protocols. JCI-accredited centers use electronic verification for drug dosing. Multidisciplinary teams monitor patients 24/7. This ensures immediate response to any treatment side effects. Advanced infusion pumps guarantee precise delivery for complex regimens.
Bookimed Expert Insight: Israeli oncology centers like Rambam and Sheba prioritize biological alternatives for sensitive patients. Medical teams often switch to blinatumomab if high toxicity occurs. This tailored approach reduces side effects while maintaining high success rates. These centers manage over 65,000 annual operations, which builds immense clinical experience. This volume allows doctors to catch minor red flags before they escalate.
Patient Consensus: Patients value the constant presence of certified nursing staff throughout every infusion. They appreciate how quickly medical teams adjust individual medications to reduce nausea and mouth sores.
Eligibility for CAR-T and advanced leukemia therapies in Israel depends on molecular profiling and physical fitness. CAR-T is reserved for relapsed or refractory cases after 2 prior treatments. Fit patients up to 75 years qualify for transplants. Targeted drugs require specific genetic markers like the Philadelphia chromosome.
Bookimed Expert Insight: Israeli oncology centers often provide faster access to CAR-T therapies through local manufacturing. Hospitals like Sheba Medical Center process cells in-house rather than shipping them abroad. This protocol reduces the wait time for patients with aggressive, late-stage leukemia.
Patient Consensus: Patients emphasize that having a dedicated caregiver is mandatory during the long outpatient recovery phase. Many find that early genetic testing helped them skip ineffective chemotherapy for targeted options.
Israeli oncology centers provide standard chemotherapy as outpatient care. Bone marrow transplants require an initial 21 to 30-day inpatient stay for isolation. Most patients remain in Israel for 2 to 6 months depending on their specific treatment protocols and recovery speed.
Bookimed Expert Insight: Israeli hospitals like Sourasky Medical Center and Hadassah offer specialized outpatient hotels nearby. These facilities bridge the gap between hospital wards and private rentals. This helps patients stay close to doctors while reducing total costs for a 3-month stay.
Patient Consensus: Patients note that staying near the clinic is vital for daily blood checks. Many suggest choosing accommodation with a kitchen to manage strict post-transplant dietary needs easily.
Israeli hematology centers manage high volumes of international pediatric and adult cases yearly. Specialized departments provide English-speaking coordinators for seamless communication. These teams handle medical records and logistics. Clinics like Sheba and Hadassah maintain survival rates of 85% to 90% for childhood blood cancers.
Bookimed Expert Insight: Israeli hospitals excel at managing complex adult relapses. This is evident through their in-house cell processing centers. Hadassah and Sheba do not outsource CAR T-cell manufacturing. This saves critical time for patients with aggressive leukemia. Such centers routinely manage patients who failed standard treatment elsewhere.
Patient Consensus: Patients note that case managers act as essential bridges during hospital stays. Most feel relieved discovering that medical instructions are clearly explained in English.
Israeli hematology centers offer haploidentical transplants when fully matched donors are unavailable. These half-match procedures use a parent, child, or sibling as a donor. Success rates for Acute Lymphoblastic Leukemia (ALL) are now comparable to matched unrelated donor transplants. Modern protocols ensure high accessibility for all patients.
Bookimed Expert Insight: Israeli oncology centers demonstrate high expertise in managing complex half-match cases. For example, Sourasky Medical Center performs over 60 bone marrow transplants annually. Top specialists there often emphasize donor age. Younger donors generally lead to better survival outcomes in ALL cases. This focus on donor selection optimizes recovery outside of standard matching.
Patient Consensus: Patients note that the half-match option provides immense relief. They appreciate that almost everyone can find a family donor. Many emphasize that while platelet recovery takes longer, the outcome feels identical to full matches.
Israeli protocols manage CNS leukemia through aggressive prevention and risk-adapted therapy. Specialists use intrathecal chemotherapy and high-dose systemic medications to cross the blood-brain barrier. Advanced options include CAR T-cell therapy and all-inclusive bone marrow transplants at JCI-accredited centers like Sourasky and Sheba.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center prioritize pediatric-inspired protocols for young adults. This approach yields higher survival rates by utilizing more aggressive CNS prophylaxis. These centers manage high-volume cases and offer 14-day diagnostic packages to confirm staging quickly. This speed is vital for preventing CNS involvement before it manifests.
Patient Consensus: Patients value the multidisciplinary teams that manage both neurological side effects and cancer. They often notes that having everything from diagnostics to transplant in one facility reduces stress.